65,437 trials
Heart Failure
Primary: Number of Participants With Post-treatment Sustained Virologic Response (SVR) — 9 Participants
Esophageal Carcinoma · Esophagogastric Junction Carcinoma
Primary: Overall Survival (OS) in All Participants — 8.4; 5.6 Months — p=0.0015
Infertility, Male · Depression
Primary: Number of Participants With Abnormal Sperm DNA Fragmentation at 6 Weeks — 0; 2 Participants
Partial Onset Seizures
Primary: Percentage of Participants With Partial-onset Seizures (POS) Who Achieved Seizure-free Status During the 26-week Maintenance Period of 4 mg Perampanel — 63.0 percentage…
Ectropion · Skin Neoplasms
Primary: Graft Size Change — 10 percent change in graft
Stable Angina
Primary: Biomarker Titer of Patients With Coronary Artery Disease — 13; 5; 60; 0.5 tilter — p=0.002
Hip Fractures
Primary: Opiate Requirements — 52.5; 65.39 Morphine mEq
Chronic Obstructive Pulmonary Disease · Asthma · Pneumococcal Infections
Primary: Number of Patients Without Exacerbations of the Underlying Disease, Antibiotic Use and Hospitalisation. — 3; 5; 1; 0 Participants — p=<0.05
Prostate Cancer · Adenocarcinoma of the Prostate
Primary: Procedure Time — 30 minutes
Advanced Nonhematologic Malignancies
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 4; 3; 7; 3 Participants
Pouchitis
Primary: Proportion of Patients With Endoscopic Remission — 3; 3 Participants
Breast Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Attenuation Correction for PET/MRI, Assessed Using Standard Uptake Values (SUVs) (Cohorts I & II)
Enteral Feeding Intolerance
Primary: Duration of Time — 19; 2.5 Minutes
Iron Deficiency Anaemia · Iron Deficiency Anemia
Primary: Incidence of Hypophosphatemia (S-phosphate Level <2 mg/dL) — 5; 42 Participants — p=<0.0001
Evaluation of SpO2 Performance
Primary: Accuracy of Oxygen Saturation (SpO2) Measurement by RMS Calculation — 3.5 percent of oxygen saturated hemoglobin